Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Anti-tumour necrosis factor (anti-TNF) therapy of patients with rheumatoid arthritis dates back to 1992, when the first proof-of-principle trials were performed in London by Maini and Feldmann. Considerable studies of the mechanism of action were performed, and insights into the way in which anti-TNF therapy delivers its benefit were obtained. In this brief review, certain aspects of knowledge acquired and the many gaps will be reviewed. Focus will be on the TNF-dependent cytokine cascade and what it means, and potential new approaches to treatment. Finally, an entertaining challenge: might many or even all unmet clinical needs be dealt with through cytokine analysis?

Original publication

DOI

10.1136/ard.2009.117143

Type

Journal article

Journal

Ann Rheum Dis

Publication Date

01/2010

Volume

69 Suppl 1

Pages

i97 - i99

Keywords

Antirheumatic Agents, Arthritis, Rheumatoid, Cognition Disorders, Cytokines, Drug Design, Humans, Postoperative Complications, Tumor Necrosis Factor-alpha